Resources/
Phil Blog
Phil Blog
Fierce Pharma: The Hidden GTN Drain: Why Specialty-Lite Brands Need To Streamline Their PA Process for Optimal Commercial Performance
For retail and specialty-lite pharmaceutical brands, the path from prescription to profit has never been more treacherous. While commercial teams focus on market access negotiations and formulary wins, a critical revenue leak often goes unnoticed: the gap between prior authorization (PA) requirements and submission rates, creating a cascade of gross-to-net (GTN) erosion that threatens long-term viability.
BioPharma Dive: Redefining Commercial Success in Speciaty-Lite
Specialty-lite products occupy a complex middle ground in pharmaceutical commercialization. Unsuitable for standard retail yet not requiring the full infrastructure of specialty pharmacies, these products face unique access barriers that traditional distribution models can’t address effectively. The solution
Press Release: PHIL Secures $60M Growth Capital from K2 HealthVentures to Accelerate AI Integration
Phil, a leading software-driven pharmaceutical commercialization platform, today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas.
BioPharma Dive: Bridging Data Gaps that Impact Retail and Specialty-Lite Success
Retail and specialty-lite brand teams are facing a paradox – they’re drowning in data yet struggling to gain actionable insight. While manufacturers collect vast amounts of information, most are still making critical business decisions based on incomplete data sets that fail to capture the full prescription journey.
Drug Channels: Harnessing the Power of Comprehensive Data to Drive GTN
Growing market access barriers are compelling retail and specialty-lite pharmaceutical manufacturers to seek new approaches to optimize revenue and enhance patient access. Traditional data sources and siloed solutions are no longer sufficient to address the challenges of formulary exclusions and rising patient out-of-pocket costs. Success in today's market requires comprehensive visibility across the patient journey to drive meaningful improvements in gross-to-net (GTN) performance.
Ready to learn more?
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.
Create a Path to Commercial Success
Our expert team can build a tailored access program that drives your brand goals.
Our Solution
About Us
